世界のアルコール性肝炎治療市場2021年-2025年

◆英語タイトル:Global Alcoholic Hepatitis Treatment Market 2021-2025
◆商品コード:IRTNTR43861
◆発行会社(リサーチ会社):Technavio
◆発行日:2021年2月26日
◆ページ数:約120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

テクナビオ社は世界のアルコール性肝炎治療市場規模が、2021年~2025年まで年平均6%成長し、695.42百万ドルに達すると予測しています。本調査レポートでは、アルコール性肝炎治療の世界市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、種類別(コルチコステロイド、キサンチン誘導体、その他)分析、顧客状況、地域別状況、企業状況、企業分析などを掲載しております。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・世界のアルコール性肝炎治療市場規模:種類別(コルチコステロイド、キサンチン誘導体、その他)
・顧客状況
・地域別状況
・企業状況
・企業分析
【レポートの概要】

Global Alcoholic Hepatitis Treatment Market 2021-2025

Technavio has been monitoring the alcoholic hepatitis treatment market and it is poised to grow by $ 695.42 mn during 2021-2025 progressing at a CAGR of 6% during the forecast period. Our report on alcoholic hepatitis treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing consumption of alcohol and availability of prognostic models for alcoholic hepatitis. In addition, increasing consumption of alcohol is anticipated to boost the growth of the market as well.

The alcoholic hepatitis treatment market analysis includes type segment and geographical landscapes.

Technavio’s alcoholic hepatitis treatment market is segmented as below:
By Type
• Corticosteroids
• Xanthine derivatives
• Others

By Geographical Landscapes
• North America
• Europe
• Asia
• ROW

This study identifies the high market penetration of corticosteroids and off-label therapies as one of the prime reasons driving the alcoholic hepatitis treatment market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on alcoholic hepatitis treatment market covers the following areas:
• Alcoholic hepatitis treatment market sizing
• Alcoholic hepatitis treatment market forecast
• Alcoholic hepatitis treatment market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading alcoholic hepatitis treatment market vendors that include Cadila Healthcare Ltd., Dr. Reddys Laboratories Ltd., Gilead Sciences Inc., Johnson & Johnson, Mylan NV, Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the alcoholic hepatitis treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/alcoholic-hepatitis-treatment-market-size-industry-analysis

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Market characteristics
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 – 2025
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Type
o Market segments
o Comparison by Type
o Corticosteroids – Market size and forecast 2020-2025
o Xanthine derivatives – Market size and forecast 2020-2025
o Others – Market size and forecast 2020-2025
o Market opportunity by Type
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2020-2025
o Europe – Market size and forecast 2020-2025
o Asia – Market size and forecast 2020-2025
o ROW – Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Competitive scenario
o Vendor landscape
o Landscape disruption
o Industry risks
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Cadila Healthcare Ltd.
o Dr. Reddys Laboratories Ltd.
o Gilead Sciences Inc.
o Johnson & Johnson
o Mylan NV
o Novartis AG
o Sanofi SA
o Sun Pharmaceutical Industries Ltd.
o Takeda Pharmaceutical Co. Ltd.
o Teva Pharmaceutical Industries Ltd.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2020 – 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 – 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2020
• 21: Type – Market share 2020-2025 (%)
• 22: Comparison by Type
• 23: Corticosteroids – Market size and forecast 2020-2025 ($ million)
• 24: Corticosteroids – Year-over-year growth 2020-2025 (%)
• 25: Xanthine derivatives – Market size and forecast 2020-2025 ($ million)
• 26: Xanthine derivatives – Year-over-year growth 2020-2025 (%)
• 27: Others – Market size and forecast 2020-2025 ($ million)
• 28: Others – Year-over-year growth 2020-2025 (%)
• 29: Market opportunity by Type
• 30: Customer landscape
• 31: Market share by geography 2020-2025 (%)
• 32: Geographic comparison
• 33: North America – Market size and forecast 2020-2025 ($ million)
• 34: North America – Year-over-year growth 2020-2025 (%)
• 35: Europe – Market size and forecast 2020-2025 ($ million)
• 36: Europe – Year-over-year growth 2020-2025 (%)
• 37: Asia – Market size and forecast 2020-2025 ($ million)
• 38: Asia – Year-over-year growth 2020-2025 (%)
• 39: ROW – Market size and forecast 2020-2025 ($ million)
• 40: ROW – Year-over-year growth 2020-2025 (%)
• 41: Key leading countries
• 42: Market opportunity by geography ($ million)
• 43: Impact of drivers and challenges
• 44: Vendor landscape
• 45: Landscape disruption
• 46: Industry risks
• 47: Vendors covered
• 48: Market positioning of vendors
• 49: Cadila Healthcare Ltd. – Overview
• 50: Cadila Healthcare Ltd. – Product and service
• 51: Cadila Healthcare Ltd. – Key offerings
• 52: Cadila Healthcare Ltd. – Key customers
• 53: Cadila Healthcare Ltd. – Segment focus
• 54: Dr. Reddys Laboratories Ltd. – Overview
• 55: Dr. Reddys Laboratories Ltd. – Business segments
• 56: Dr. Reddys Laboratories Ltd. – Key offerings
• 57: Dr. Reddys Laboratories Ltd. – Key customers
• 58: Dr. Reddys Laboratories Ltd. – Segment focus
• 59: Gilead Sciences Inc. – Overview
• 60: Gilead Sciences Inc. – Product and service
• 61: Gilead Sciences Inc. – Key offerings
• 62: Gilead Sciences Inc. – Key customers
• 63: Gilead Sciences Inc. – Segment focus
• 64: Johnson & Johnson – Overview
• 65: Johnson & Johnson – Business segments
• 66: Johnson & Johnson – Key offerings
• 67: Johnson & Johnson – Key customers
• 68: Johnson & Johnson – Segment focus
• 69: Mylan NV – Overview
• 70: Mylan NV – Business segments
• 71: Mylan NV – Key offerings
• 72: Mylan NV – Key customers
• 73: Mylan NV – Segment focus
• 74: Novartis AG – Overview
• 75: Novartis AG – Business segments
• 76: Novartis AG – Key offerings
• 77: Novartis AG – Key customers
• 78: Novartis AG – Segment focus
• 79: Sanofi SA – Overview
• 80: Sanofi SA – Business segments
• 81: Sanofi SA – Key offerings
• 82: Sanofi SA – Key customers
• 83: Sanofi SA – Segment focus
• 84: Sun Pharmaceutical Industries Ltd. – Overview
• 85: Sun Pharmaceutical Industries Ltd. – Business segments
• 86: Sun Pharmaceutical Industries Ltd. – Key offerings
• 87: Sun Pharmaceutical Industries Ltd. – Key customers
• 88: Sun Pharmaceutical Industries Ltd. – Segment focus
• 89: Takeda Pharmaceutical Co. Ltd. – Overview
• 90: Takeda Pharmaceutical Co. Ltd. – Product and service
• 91: Takeda Pharmaceutical Co. Ltd. – Key offerings
• 92: Takeda Pharmaceutical Co. Ltd. – Key customers
• 93: Takeda Pharmaceutical Co. Ltd. – Segment focus
• 94: Teva Pharmaceutical Industries Ltd. – Overview
• 95: Teva Pharmaceutical Industries Ltd. – Business segments
• 96: Teva Pharmaceutical Industries Ltd. – Key offerings
• 97: Teva Pharmaceutical Industries Ltd. – Key customers
• 98: Teva Pharmaceutical Industries Ltd. – Segment focus
• 99: Currency conversion rates for US$
• 100: Research Methodology
• 101: Validation techniques employed for market sizing
• 102: Information sources
• 103: List of abbreviations



【掲載企業】

Cadila Healthcare Ltd., Dr. Reddys Laboratories Ltd., Gilead Sciences Inc., Johnson & Johnson, Mylan NV, Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のアルコール性肝炎治療市場2021年-2025年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆